Phase 3 Clinical Trial

Princeton, New Jersey, Tokyo, Japan & Cambridge, Massachusetts, August 12, 2026 Taiho Oncology, Taiho Pharmaceutical, and Cullinan Therapeutics announced...

FOSTER CITY, Calif., August 13, 2026 Sagimet Biosciences Inc. announced that the U.S. Food and Drug Administration (FDA) has...

Boston, Massachusetts, August 11, 2026 Rhythm Pharmaceuticals announced that the United Kingdom’s Medicines and Healthcare products Regulatory Agency (MHRA)...

LONDON, UK; SOLANA BEACH, California; and AHMEDABAD, India, August 11, 2026 Mereo BioPharma Group plc and Sentynl Therapeutics, Inc.,...

Plainsboro, New Jersey, August,11, 2026 Novo Nordisk has announced the nationwide U.S. launch of Awiqli® (insulin icodec-abae) injection 700...

Basel, Switzerland & Lincolnshire, Illinois, August,11, 2026 Vaderis Therapeutics, a clinical-stage biopharmaceutical company focused on targeted therapies for rare...

OCALA, Fla., August 10, 2026 AIM ImmunoTech Inc. reported its second-quarter 2026 financial results and highlighted continued progress in...

SOUTH SAN FRANCISCO, California, August 10, 2026 Alumis Inc. announced topline long-term results from the ongoing Phase 3 ONWARD3...

San Diego, California, USA, August 8, 2026 Neurocrine Biosciences, Inc. has initiated a Phase 1 first-in-human clinical study evaluating...

Toronto, Ontario, Canada, August 8, 2026 Regeneron Canada Company announced that Health Canada has approved Libtayo® (cemiplimab for injection)...